Kite Pharma, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2013 | $16 M | No. 2 | $10 to $50 million | equity | SEC | |
| Feb 2011 | $12 M | No. 1 | $10 to $50 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Kite Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (May 2013).
SEC Form D · May 2013
It delivers 1 product named in the sources below.
See Products and services
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2013
In its own words
How the company describes itself to search engines on its website, word for word.
“Kite is dedicated to curing cancer. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline.”
Source: The company's website · as of Nov 15, 2026
Products#
1 named by the sources below.
- cancer immunotherapy
Wikidata · Wikidata: product or material produced (P1056)
Services#
No services of Kite Pharma, Inc. are on record.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Roy Doumani | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 40 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Aya Jakobovits | Executive officer | May 2013 |
| Gloria S. Lee | Executive officer | Mar 2011 |
| Arie S. Belldegrun | Director | May 2013 |
| Aya Jakobovits | Director | May 2013 |
| David A. Bonderman | Director | May 2013 |
| Farah B. Champsi | Director | May 2013 |
| Joshua A. Kazam | Director | May 2013 |
| Ran B. Nussbaum | Director | May 2013 |
| Roy B. Doumani | Director | May 2013 |
| Steven B. Ruchefsky | Director | May 2013 |
About
Biomedical engineering company that develops cancer immunotherapy products.